SCHEMBL4413896

SCHEMBL4413896

Fc1ccc(CNCCN(CCNCc2ccc(F)c(F)c2)Cc2ccc(CNCc3ccccn3)cc2)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
L3MBTL1 Q9Y468 6/20 0.46
ALDH1A1 P00352 3/20 0.46
CHRM2 P08172 1/20 0.43
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
HTT P42858 2/20 0.41
ALOX15 P16050 1/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MAPT P10636 1/20 0.40
LIN28A Q9H9Z2 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
SMARCA2 P51531 1/20 0.40
POLB P06746 1/20 0.40
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
GAA P10253 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4404505 0.89 CHRM2 (0.53) KDM4EL3MBTL1ALDH1A1CHRM2MEN1
SCHEMBL4404341 0.88 KDM4E (0.50) KDM4EL3MBTL1ALDH1A1CHRM2MEN1
SCHEMBL4413514 0.88 KDM4E (0.50) KDM4EL3MBTL1ALDH1A1CHRM2MEN1
SCHEMBL4412232 0.86 KDM4E (0.51) KDM4EL3MBTL1ALDH1A1CHRM2MEN1
SCHEMBL4414888 0.86 PRMT1 (0.49) L3MBTL1ALDH1A1HTTSMN1; SMN2POLB
SCHEMBL4414892 0.85 SMARCA2 (0.56) KDM4EL3MBTL1ALDH1A1CHRM2MEN1
SCHEMBL4409089 0.85 CHRM2 (0.57) KDM4EL3MBTL1ALDH1A1CHRM2MEN1
SCHEMBL4408929 0.84 KMT2A (0.54) KDM4EL3MBTL1ALDH1A1CHRM2MEN1
SCHEMBL4413889 0.83 KDM4E (0.56) KDM4EL3MBTL1ALDH1A1CHRM2MEN1
SCHEMBL14293611 0.82 CHRM2 (0.48) KDM4EL3MBTL1ALDH1A1CHRM2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1608352-B1 POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES TAIGEN BIOTECHNOLOGY CO LTD (TW) 2009-12-30 EP disclosed
US-7504422-B2 Polyamine compounds TAIGEN BIOTECHNOLOGY CO. LTD. (TW) 2009-03-17 US disclosed
US-7504422-B2 Polyamine compounds TAIGEN BIOTECHNOLOGY CO. LTD. (TW) 2009-03-17 US disclosed
US-7504422-B2 Polyamine compounds TAIGEN BIOTECHNOLOGY CO. LTD. (TW) 2009-03-17 US disclosed
US-7399776-B2 Polyamine compounds for treating chemokine receptor mediated diseases TAIGEN BIOTECHNOLOGY (TW) 2008-07-15 US disclosed
US-7399776-B2 Polyamine compounds for treating chemokine receptor mediated diseases TAIGEN BIOTECHNOLOGY (TW) 2008-07-15 US disclosed
US-7399776-B2 Polyamine compounds for treating chemokine receptor mediated diseases TAIGEN BIOTECHNOLOGY (TW) 2008-07-15 US disclosed
US-20080058382-A1 POLYAMINE COMPOUNDS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-03-06 US disclosed
US-20080058382-A1 POLYAMINE COMPOUNDS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-03-06 US disclosed
US-20080058382-A1 POLYAMINE COMPOUNDS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-03-06 US disclosed
WO-2008021788-A2 POLYAMINE COMPOUNDS TAIGEN BIOTECHNOLOGY CO., LTD. (CN) 2008-02-21 WO disclosed
US-20050043366-A1 Polyamine compounds for treating chemokine receptor mediated diseases TAIGEN BIOTECHNOLOGY (TW) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043366-A1 Polyamine compounds for treating chemokine receptor mediated diseases CCL2, CCR2, CCR5 KDM4E 3882/4885L3MBTL1 2576/4885ALDH1A1 1278/4885
US-20080058382-A1 POLYAMINE COMPOUNDS SRM, SMS, SMOX KDM4E 1061/4885L3MBTL1 1477/4885ALDH1A1 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.